KRYS - Krystal Biotech raises $200M via stock offering

Krystal Biotech (NASDAQ:KRYS) has priced its public offering of ~2.7M shares of common stock, at $75.00/share, for expected gross proceeds of ~$200M. Underwriters' over-allotment is an additional 400K shares. All of the shares will be sold by the Company other than up to 200K that may be sold by the selling stockholders. Net proceeds will be used for commercialization of VYJUVEK for dystrophic epidermolysis bullosa, if approved; to advancement of product candidates; to accelerate the Company’s emerging respiratory pipeline; for working capital and general corporate purposes. Closing date is December 3, 2021. Previously (Nov. 29): Krystal Biotech to raise $200M in stock offering

For further details see:

Krystal Biotech raises $200M via stock offering